Research programme: irinotecan prodrug - Diatos/Drais

Drug Profile

Research programme: irinotecan prodrug - Diatos/Drais

Alternative Names: DTS-108

Latest Information Update: 21 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diatos
  • Class Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Jan 2009 Added drug classes
  • 22 Dec 2008 DTS 108 licensed to Drais Pharmaceuticals worldwide
  • 17 Oct 2007 Regulatory toxicology program for DTS 108 has been initiated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top